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Abstract:  
Donohue syndrome is a rare congenital syndrome of insulin-resistance and abnormal 
glucose homeostasis, caused by mutations in the insulin receptor (INSR) gene. It is 
characterized by specific phenotypic and clinical features and the diagnosis is based 
on clinical, biochemical and genetic criteria.  
We report two siblings with Donohue syndrome (cases 1, 2) with multiple clinical and 
biochemical characteristics. Both patients shared the same mutation and presented 
with intra-uterine growth restriction, failure to thrive, fasting hyperinsulinaemic 
hypoglycaemia and episodic post-prandial hyperglycaemia. Less common clinical 
features were also present, such as atrial septal defect and biventricular hypertrophy, 
clotting disorders, abnormal liver function tests and nephrocalcinosis. Interestingly, 
two previously unrecognized manifestations of the syndrome were also identified: 
severe gastrointestinal dysmotility (case 1) and exocrine pancreatic insufficiency 
(case 2). 
The co-existence of all the above clinical features makes these cases extremely rare. 
Gastrointestinal dysmotility should always be considered as a potentially fatal feature 
in patients with the syndrome, due to the complexity of the possible co-morbidities.  
In addition, our clinical experience for the first time suggests that pancreatic exocrine 
insufficiency may offer a possible explanation for the growth retardation observed in 
some patients with this syndrome. Our finding that replacement treatment with 
pancreatic enzymes improved weight gain (case 2) implies that all patients with 
Donohue syndrome should be investigated for exocrine pancreatic insufficiency.  
 
Key words: Donohue, gastrointestinal dysmotility, pancreatic exocrine insufficiency, 
insulin resistance, hyperinsulinism. 
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Introduction  
Donohue syndrome is a rare autosomal recessive condition characterized by abnormal 
glucose homeostasis, severe insulin resistance and typical clinical and dysmorphic 
features. Common clinical findings include intrauterine and postnatal growth 
retardation, large and low-set ears, prominent eyes, broad nasal tip, enlargement of 
organs and soft tissues, reduced adipose tissue, muscular atrophy, a distended 
abdomen and enlarged external genitalia and nipples. Common biochemical findings 
include fasting hypoglycaemia, fasting hyperinsulinism, increased fasting C-peptide 
and post-prandial hyperglycaemia, with impaired insulin sensitivity being the 
underlying disorder (1). 
 
The syndrome is caused by severe loss-of-function mutations in the insulin receptor 
(INSR) gene and was first described by Donohue in 1948
 
(2), and termed 
‘leprechaunism’ in 1954 (3). The diagnosis is made on clinical, biochemical and 
genetic grounds. Donohue syndrome is the most severe type of INSR disorder and its 
prognosis is generally poor. Many affected patients die in infancy, with the majority 
not reaching the second year of life. Death is usually related to infections
 
(4).    
 
We report 2 siblings with Donohue syndrome who were observed to have additional 
clinical features (severe gastrointestinal dysmotility and pancreatic exocrine 
insufficiency) that have not been described previously.     
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Case reports  
Here we report two cases of female infants with Donohue syndrome and highlight two 
additional clinical manifestations, which have not been reported previously (table 1). 
Case 1: Female infant born at full term by elective Caesarian section for previous 
sections, with severe intrauterine growth retardation (IUGR) and a birth weight of 1.4 
Kg (-5.28 SDS). She was survivor of a dichorionic diamniotic twin pregnancy and the 
other twin died in utero during the first trimester. She was the 5
th
 child of 
consanguineous (first cousins) parents and her four siblings, aged 9, 7, 6 and 4 years, 
were all healthy, with no dysmorphic features or metabolic disorders. Multiple 
dysmorphic features were identified, including wrinkled skin all over the body with 
absence of cutaneous fat, microcephaly, hypertelorism, hypertrichosis, hypertrophied 
gums and lips. Additional clinical findings were mild clitoromegaly, mild breast 
enlargement, bilateral inguinal hernia and acanthosis nigricans. 
 
Soon after birth she was noted to have pre-meal hypoglycaemia and post-feed 
hyperglycaemia. She had fasting insulin of >6945pmol/l and random insulin of 
2634pmol/l and was started on Metformin. At the age of 3 months she was admitted 
to hospital with fever and was diagnosed with meningitis. At the age of 6 months, she 
was transferred to Great Ormond Street Hospital for multidisciplinary medical care. 
The blood glucose concentrations ranged between 3-14mmol/L and serum insulin 
levels were >300mU/L when plasma glucose was 9mmol/L.  Treatment with 
recombinant IGF-1 was started for the management of hyperglycaemia at the initial 
dose of 35mcg/kg/day to a final dose of 90mcg/kg/day. Good glucose control was 
achieved with only few hypoglycaemic episodes, which responded to feeds.  
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Genetic analysis detected a homozygous INSR sequence variant, c.1093G>T, in exon 
4 of the INSR gene. This mutation was predicted to result in an abnormal INSR 
protein, p.(Gly365Trp).{Mutation Taster:  Prediction disease causing (prob: 
0.999999999999523). PolyPhen-2:   PROBABLY DAMAGING with a score of 1.000}. 
As far as we are aware, this variant has not been reported before, which is consistent 
with a diagnosis of Donohue syndrome. Sequence analysis of DNA from both 
parents, confirmed that they are both heterozygous carriers of this variant, indicating 
that it was biparentallly inherited. The twin sibling possibly died of the same 
condition. 
 
A cardiac echocardiogram revealed severe biventricular hypertrophy and secundum 
atrial septal defect (ASD) with moderate left to right shunt. The patient also had 
narrower right ear canal, as well as difficult airway, right-sided choanal atresia, small 
chest and required oxygen to maintain her saturation.  
 
She subsequently developed abdominal distention and had a rectal biopsy. 
Hirschsprung disease was excluded, but the cause of the abdominal distention 
remained undefined. She was also noted to have elevated liver enzymes without 
hepatosplenomegaly. Clotting abnormalities of unknown cause were also present, 
with low levels of factors II, VII, IX and XI. Vitamin K supplementation was started 
at the age of 6 months. 
 
Medullary nephrocalcinosis with mild hydronephrosis and enlarged ovaries with 
multicystic appearances were identified on renal and pelvic USS, respectively. 
Oestradiol and testosterone levels were raised.  Significant failure to thrive and poor 
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growth development, a typical clinical characteristic of Donohue syndrome, was also 
manifest, as shown in the growth chart (figure 1).  
 
At the age of 7 months, the patient’s abdomen became acutely distended and her 
clinical picture was indicative of abdominal obstruction. She underwent distal 
ileostomy, but because of difficult intubation, 3 days after surgery she developed 
seizures secondary to global hypoxic brain injury with infarction of the cerebral 
hemispheres. The life-limiting diffuse brain damage in combination with deteriorating 
abdominal distension, desaturations and stoma losses that required fluid resuscitation, 
led to her death at the age of 10 months.  
 
Case 2: This is the 7th child of the same parents, sibling of case 1, and is now 10 
months old. She was delivered at 38
+3
 weeks of gestation by elective caesarean 
section and was small for gestational age, with a birth weight of 1.94 Kg (-3.52 SDS). 
Soon after birth, she developed hypoglycaemia with blood glucose concentration of 
1.9mmol/L, which resolved with intravenous fluid administration of 10% dextrose 
and, subsequently, total parenteral nutrition (TPN). She was also noted to have mild 
facial dysmorphism, microcephaly and was also markedly hirsute. Her phenotypic 
features were characteristic of Donohue syndrome. Intermittent abdominal distension 
with distended bowel loops was noted from birth and was referred to our hospital on 
day 9 of life. 
Donohue syndrome was confirmed by the same homozygous mutation in the INSR 
gene {c.1093G>T, p.(Gly365Trp)} as in case 1, found by fluorescent sequencing 
analysis.  
 
In addition to hypoglycaemia on the first day of life, the patient exhibited fluctuating 
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blood glucose concentrations, ranging between 3-11mmol/L, with fasting 
hypoglycaemia and post-prandial hyperglycaemia, particularly after breastfeeding. 
Serum insulin levels were also very high (>300mU/L), which is in keeping with the 
diagnosis of Donohue syndrome. 
Cardiac echocardiogram on day 9 of life showed a moderate sized secundum atrial 
septal defect, with mild but increasing signs of left to right shunt. The pulmonary 
arteries were enlarged and a modest concentric left ventricular hypertrophy was 
detected on day 20 of life, but could not be seen at the age of 5 months. An ASD 
repair and aortopexy were successfully performed. 
 
Over the first 3 months of life there was progressive volume loss and partial collapse 
of the left lung. The enlarged left atrium or a plug compressed the left main bronchus 
presumably, and the trachea was slightly narrowed. Whereas dilated pulmonary artery 
branches probably caused compression of the airways, multiple consolidations on a 
CT scan were in keeping with aspirations. As a result, the patient suffered from 
respiratory distress with prolonged oxygen requirement. Muscular hypotonia of 
unknown origin, that could be an additional cause of the patient’s respiratory distress, 
became apparent after the 5
th
 month of life.  
 
An additional clinical sign recurrent pyrexia associated with tachycardia and 
tachypnoea was present despite changes in antibiotic therapy and use of broad-
spectrum antibiotics. Blood cultures were persistently negative and inflammatory 
markers were never raised. The cause of the pyrexia is unclear despite extensive 
investigations, including tuberculosis screen, but a potential focus could be the upper 
left lobe consolidation. Her umbilical cord was retained to beyond 1 month and, when 
separated, the umbilical stump looked clean and appropriately healed and there was 
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no evidence of omphalitis. She had otherwise normal skin and a normal neutrophil 
count. A basic immunodeficiency screen of lymphocyte subsets, T memory panel and 
basic immunoglobulins did not reveal any abnormalities. 
Growth retardation and poor weight gain were also present on maximum feed volume 
and calories (figure 1).  
 
Another clinical finding was mildly deranged clotting, disturbed liver function tests 
and low factor II, VII, IX and XI levels (table 2). Vitamin K1 and PIVKA-II (a 
functional marker of Vitamin K status) concentrations were undetectable.  
 
On testing of her urine on the 21
st
 day of life, there was increased excretion of 
calcium, with raised urine calcium/creatinine ratio. The ultrasound of both kidneys 
showed bilateral nephrocalcinosis. Urine albumin to creatinine ratio was also raised 
(table 2). 
Moderate and severe pancreatic exocrine insufficiency was confirmed on two 
occasions (on day 49 and at 4 months of life, respectively) by abnormal pancreatic 
elastase-1 levels (table 2). Fat globules were also present in the faeces. Vitamin K and 
Vitamin D levels were undetectable and supplementation of both vitamins was 
required. Since the pancreatic exocrine insufficiency was treated with pancreatic 
enzymes, our patient’s weight gain has improved (figure 1).  
 
Discussion 
Most of our patients’ clinical features have been previously described in literature. 
ASD has been reported in extreme insulin resistance (Rabson-Medenthal phenotype)
 
(5). Two cases of obstructive hypertrophic cardiomyopathy have been recently 
reported in patients with Donohue syndrome (6,7). A literature survey has revealed 
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that hypertrophic cardiomyopathy was present in 30% of patients with the syndrome 
and can be fatal (6).  
 
Hyperbilirubinaemia and liver dysfunction (elevated AST and ALT, cholestasis and 
coagulation disorder) have also been reported in an infant with Donohue syndrome 
(8). With regards to renal function, a case of progressive obstructive cardiomyopathy 
and renal tubular dysfunction has been described (9). In addition, insulin receptor 
dysfunction has previously been associated with hypercalciuria and nephrocalcinosis, 
with no other consistent abnormality of renal function (10).  
 
The co-existence of all the above clinical features, in association with the complexity 
and severity of the clinical presentations, makes these cases extremely rare. What is 
more, the identification of two clinical features that have not been previously reported 
in patients with insulin resistance syndromes, adds to the rarity of these cases. To the 
best of our knowledge, no data is available in the literature associating gastrointestinal 
dysmotility or pancreatic exocrine insufficiency with Donohue syndrome. The 
concurrence of two infrequent clinical entities in each of our patients either suggests 
that there is a wider, than previously estimated, variability in the clinical features of 
Donohue syndrome or, more likely, that our patients’ parental consanguinity resulted 
in the expression of more than one disadvantageous recessive phenotypes. Our cases 
highlight the importance of recognising gastrointestinal dysmotility as a potentially 
fatal presentation of Donohue syndrome, due to the possible severe comorbidities of 
the patients with the syndrome.  The exact underlying cause of the gastrointestinal 
dysmotility is still unclear. Early recognition and surgical input may improve the 
outcome. 
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In addition, the identification for the first time of pancreatic exocrine insufficiency in 
a patient with Donohue syndrome may provide an additional mechanism of growth 
retardation in these patients. It is well known that weight loss is one of the major 
clinical manifestations of pancreatic exocrine insufficiency, together with muscle 
wasting and steatorrhoea, as a result of malabsorption of essential nutrients, 
particularly fat. The most common conditions that cause pancreatic exocrine 
insufficiency are chronic pancreatitis, autoimmune pancreatitis, cystic fibrosis, 
Shwachman-Diamond syndrome, coeliac disease and Crohn’s disease. Our finding 
that replacement with pancreatic enzymes enhanced our patient’s growth and weight 
gain, further supports the hypothesis that pancreatic exocrine insufficiency 
contributed to the poor weight gain of this patient.  Hence, we recommend that all 
patients with Donohue syndrome should be investigated for possible pancreatic 
exocrine insufficiency of all the possible causes, as it is a treatable clinical feature. 
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Table 1: Clinical Phenotypic features of the 2 siblings (case 1 and case 2) 
Clinical presentation/system 
review 
Case 1 Case 2 
IUGR ✓ ✓ 
Failure to thrive postnatally ✓ ✓ 
Dysmorphic features - 
Hypertrichosis 
✓ ✓ 
Abnormal glucose homeostasis ✓ ✓ 
Cardiovascular: 
Biventricular hypertrophy - 
ASD 
 
✓ 
 
✓ 
Respiratory system: 
Narrow ear canal, choanal 
atresia, small thorax 
 
✓ 
 
✕ 
Oxygen requirement ✓ ✓ 
Dilated pulmonary artery 
branches 
✕ ✓ 
Gastrointestinal/Hepatobiliary 
system: 
Abdominal distention 
 
                                                  
✓ 
 
                                                  
✓ 
GI dysmotility ✓ ✕ 
Pancreatic exocrine 
insufficiency 
✕ ✓ 
Liver dysfunction ✓ ✓ 
Others: 
Clotting abnormalities (Factors 
II, VII, IX, XI) 
 
✓ 
 
✓ 
Nephrocalcinosis-
hydronephrosis 
✓ ✓ 
Muscular hypotonia ✕ ✓ 
Persistent pyrexia ✕ ✓ 
Enlarged ovaries ✓ ✕ 
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Table 2: Haematological and biochemical findings 
 Case 1 Case 2 
 At the time of admission         
(6 months of age) 
Most recent  
(10 months age) 
At the time of admission 
(9 days of life) 
Most recent  
(10 months age) 
Full blood count:     
Haemoglobin (g/L)  
(Normal range: 100-135) 
99 78  99 98 
White cell count (x109/L)  
(Normal range: 6.0-18.0) 
9.06 7.91  8.04 11.08 
Neutrophils/Lymphocytes
/Monocytes/Eosinophils 
(x109/L) 
3.58/3.9/1.19/0.37 3.42/2.88/0.81/0.78 1.92/4.98/0.83/0.3 4.95/4.66/1.26/0.16 
Platelets (x109/L)  
(Normal range: 150-450) 
196 88  494 143 
Clotting:     
Prothombin time (sec) 
(Normal range: 9.6-11.8) 
20.1 22.6  16.1 15.3 
APTT (sec)  
(Normal range: 28-40) 
43.2 63.9  62.5 50.3 
Fibrinogen (g/L)  
(Normal range: 1.7-4) 
1.0 1.0  0.8 1.8 
Factor assays:     
Factor II (IU/dl)  
(Normal range: 34-102) 
Factor V (IU/dl) 
(Normal range: 50-150) 
30 
 
101 
 32 
 
129 
 
Factor VII (IU/dl) 
(Normal range: 42-138) 
Factor VIII (IU/dl) 
(Normal range: 50-125) 
16 
 
238.8 
 15 
 
142.6 
 
Factor IX (IU/dl) 
(Normal range: 21-81) 
Factor XI (IU/dl) 
(Normal range: 27-79) 
16.1 
 
25 
 19.3 
 
23 
 
Factor XII (IU/dl) 
(Normal range: 17-81) 
65  52  
Liver Function test: 
Total bilirubin (μmol/L) 
 
26 
 
44 
 
120 
 
Alanine transaminase 
(U/L)  
(Normal range: 12-47) 
68 58  25 47 
Albumin (g/L) 
(Normal range: 34-42) 
GGT (U/L)  
(Normal range: 20-148) 
32 
 
 
20  20 
 
473 
31 
Renal Function test: 
Sodium (mmol/L) 
 
136 
 
137 
 
142 
 
145 
Potassium (mmol/L) 4.4 3.5 5 3.8 
Urea (mmol/L) <0.7 5.4 (0.7-5.0) 0.9 12 
Creatinine (μmol/L) 
 
8 11 (13-32) 14 11 
Urine Calcium/ 
creatinine ratio 
(mmol/mmol Creat) 
(Normal range: 0.06-0.74) 
 
Urine albumin/creatinine 
ratio (mg/mmol) 
(Normal range: 1.7 - 12.2) 
 
 
 
Insulin (mU/L) 
Glucose (mmol/L) 
 
Pancreatic elastase-1 
(μg/g) 
(Moderate exocrine 
insufficiency: 100-199) 
1.25 
 
 
 
 
 
 
 
 
 
 
>300 
8 
 
 
Not measured 
1.34 (0.09-2.2) 
 
 
 
 
 
 
 
 
 
 
 
8.25 
 
 
3.06 
 
 
 
 
46.3 
 
 
 
 
 
>300 
4.5 
 
 
197 
7.9 
 
 
 
 
 
 
 
 
 
 
 
9.16 
 
 
>500 (post-
replacement, at 5 
months of age) 
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Figure 1: Growth chart case 1 and case 2 
Case 1: 
 
 
Case 2: 
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